Ikonisys SA (ALIKO) - Total Liabilities
Based on the latest financial reports, Ikonisys SA (ALIKO) has total liabilities worth €7.50 Million EUR (≈ $8.77 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALIKO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Ikonisys SA - Total Liabilities Trend (2019–2024)
This chart illustrates how Ikonisys SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ALIKO total asset value.
Ikonisys SA Competitors by Total Liabilities
The table below lists competitors of Ikonisys SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mgenplus Co. Ltd.
KQ:032790
|
Korea | ₩22.39 Billion |
|
Nucletron Electronic Aktiengesellschaft
F:NUC
|
Germany | €2.08 Million |
|
Z-Com Inc
TWO:8176
|
Taiwan | NT$162.30 Million |
|
Essen Tech Co. Ltd
KQ:043340
|
Korea | ₩43.71 Billion |
|
BRIDGETEC Corp
KQ:064480
|
Korea | ₩11.50 Billion |
|
Wooree E&L Co. Ltd
KQ:153490
|
Korea | ₩51.22 Billion |
|
Naas Technology Inc ADR
NASDAQ:NAAS
|
USA | $1.26 Billion |
|
Sarawak Consolidated Industries Bhd
KLSE:9237
|
Malaysia | RM201.93 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Ikonisys SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Ikonisys SA net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ikonisys SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ikonisys SA (2019–2024)
The table below shows the annual total liabilities of Ikonisys SA from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €13.14 Million ≈ $15.37 Million |
+156.73% |
| 2023-12-31 | €5.12 Million ≈ $5.99 Million |
+26.61% |
| 2022-12-31 | €4.04 Million ≈ $4.73 Million |
+61.43% |
| 2021-12-31 | €2.50 Million ≈ $2.93 Million |
+5.01% |
| 2020-12-31 | €2.39 Million ≈ $2.79 Million |
+16.79% |
| 2019-12-31 | €2.04 Million ≈ $2.39 Million |
-- |
About Ikonisys SA
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the flu… Read more